Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta W Scherer

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
The Cochrane Database of Systematic Reviews|February 20, 2025
Cardiovascular training for fatigue in people with cancerCarina Wagner, Moritz Ernst, Nora Cryns, et al.
Trials|January 20, 2018
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trialRoberta W Scherer, Lea Drye, Jacobo Mintzer, et al.
BMC Ophthalmology|November 23, 2006
Development and validation of a computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression TrialSteven E Feldon, Lori Levin, Roberta W Scherer, et al.
JAMA Ophthalmology|October 11, 2019
Evaluation of Systematic Reviews of Interventions for Retina and Vitreous ConditionsJimmy T Le, Riaz Qureshi, Claire Twose, et al.
Critical Reviews in Toxicology|September 18, 2013
A survey of frameworks for best practices in weight-of-evidence analysesLorenz R Rhomberg, Julie E Goodman, Lisa A Bailey, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 29, 2020
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With MethylphenidateChristopher H van Dyck, Amy F T Arnsten, Prasad R Padala, et al.
Journal of Clinical Epidemiology|April 26, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
JAMA Neurology|September 27, 2021
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical TrialJacobo Mintzer, Krista L Lanctôt, Roberta W Scherer, et al.
BMJ (Clinical Research Ed.)|April 24, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 23, 2020
Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of InstrumentsKrista L Lanctôt, Roberta W Scherer, Abby Li, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
The Cochrane Database of Systematic Reviews|February 20, 2025
Cardiovascular training for fatigue in people with cancerCarina Wagner, Moritz Ernst, Nora Cryns, et al.
Trials|January 20, 2018
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trialRoberta W Scherer, Lea Drye, Jacobo Mintzer, et al.
BMC Ophthalmology|November 23, 2006
Development and validation of a computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression TrialSteven E Feldon, Lori Levin, Roberta W Scherer, et al.
JAMA Ophthalmology|October 11, 2019
Evaluation of Systematic Reviews of Interventions for Retina and Vitreous ConditionsJimmy T Le, Riaz Qureshi, Claire Twose, et al.
Critical Reviews in Toxicology|September 18, 2013
A survey of frameworks for best practices in weight-of-evidence analysesLorenz R Rhomberg, Julie E Goodman, Lisa A Bailey, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|May 29, 2020
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With MethylphenidateChristopher H van Dyck, Amy F T Arnsten, Prasad R Padala, et al.
Journal of Clinical Epidemiology|April 26, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
JAMA Neurology|September 27, 2021
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical TrialJacobo Mintzer, Krista L Lanctôt, Roberta W Scherer, et al.
BMJ (Clinical Research Ed.)|April 24, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trialsDaniela R Junqueira, Liliane Zorzela, Susan Golder, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 23, 2020
Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of InstrumentsKrista L Lanctôt, Roberta W Scherer, Abby Li, et al.
Pageof 7